#United States #New York #Clinical Trials #Pomerantz LLP #XOMA Royalty

Pomerantz Law Firm Investigates Claims for XOMA Investors

Pomerantz LLP, a notable law firm recognized for its work in securities class action litigation, has initiated an investigation regarding potential claims made by investors in XOMA Royalty Corporation. This investigation has arisen in light of troubling developments surrounding the company's recent clinical trials.

The focus of the inquiry pertains to whether XOMA and certain individuals associated with it, including its officers and directors, engaged in practices that may constitute securities fraud or other unlawful business activities. Investors affected by this situation are advised to connect with Danielle Peyton at Pomerantz LLP for further guidance and potential participation in legal action.

Recent Developments

On December 11, 2025, Rezolute, Inc., a development partner of XOMA, released a press statement that highlighted disappointing results from its Phase 3 sunRIZE clinical trial. The study sought to evaluate the efficacy of ersodetug in treating patients suffering from congenital hyperinsulinism (HI). Unfortunately, the trial did not achieve its primary objective, which was to demonstrate a significant reduction in hypoglycemia events as measured by self-monitored blood glucose levels.

Despite the study indicating a 45% reduction in hypoglycemia incidents at the highest dosage of 10 mg/kg, this result fell short of statistical significance when compared to the placebo, which saw a 40% improvement. Moreover, the primary endpoint concerning the average daily percentage of time spent in hypoglycemia also failed to meet expectations, with a mere 25% reduction noted at the highest dose versus a 5% increase in the placebo group.

As a direct consequence of this disappointing news, the stock price of XOMA plummeted dramatically, witnessing a decline of $7.82 per share, a staggering 22.76%, to settle at $25.39 on December 19, 2025.

About Pomerantz LLP

Founded by Abraham L. Pomerantz, often referred to as the 'dean of the class action bar', Pomerantz LLP has established itself as a leading authority in corporate securities and antitrust class litigation. With over 85 years of experience, the firm is dedicated to advocating for victims of securities fraud and corporate misconduct, successfully recovering multimillion-dollar settlements for its clients.

As the legal landscape continues to evolve, investors associated with XOMA are encouraged to stay informed about the ongoing investigation and consider their options in light of recent developments.

For more information or to participate in the ongoing investigation, potential class members or current investors can contact Pomerantz LLP at 646-581-9980 ext. 7980 or via email at [email protected].

In a time when transparency and accountability have become paramount for investors, this investigation serves as a crucial reminder of the importance of vigilance in the corporate space. Investors must remain aware of the implications of investment choices and the accountability of corporate entities involved in the healthcare and securities sectors.